Novel inhalation formulations of polymyxins

Back to all technologies
Download as PDF
2020-ZHOU-68990
Intravenous and oral antibiotics are not always effective for lung infections due to limited drug exposure at the infection site and bacterial resistance.

Researchers at Purdue University have developed a novel combination therapy of polymyxins for treating bacterial lung infections. Polymyxins have often been used as the last-line resort for infections caused by multi-drug resistant Gram-negative 'superbugs'; but inhaled polymyxins can cause toxicity in the lungs. The novel formulations developed by Purdue researchers create a powerful therapeutic option with better antibacterial killing and much-reduced toxicity than the currently used inhaled polymyxin B and colistin. Furthermore, the Purdue dry powder formulation shows promise as an inhaled therapy, with satisfactory stability and high aerosolization performance. These innovative inhalation formulations promise a life-saving option for patients suffering from bacterial lung infections, including people infected by multidrug-resistant Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacterales.

Advantages:
-Enhanced efficacy
-Decreased drug resistance
-Improved safety

Potential Applications:
-Pharmaceuticals
-Biomedical
-Medicine
May 3, 2021
PCT-Gov. Funding
WO
(None)
(None)

Jul 2, 2020
Provisional-Gov. Funding
United States
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org